This listing of claims will replace all prior versions of claims in the application:

Listing of Claims: Please amend the claims as follows:

We claim:

Claim 1. (Currently Amended) ~~Solid crystal form~~ A crystal of an ~~anti-EGFR~~ anti-epidermal growth factor receptor (anti-EGFR) antibody or a variant thereof or a fragment thereof ~~and/or one of its variants and/or fragments~~ which ~~results in~~ forms a biologically active antibody protein when dissolved or suspended ~~through dissolution or suspension~~ in an aqueous medium, ~~obtainable by precipitation of the antibody~~ said crystal being obtained by a process comprising

precipitating an aqueous solution or suspension of said anti-EGFR antibody or a variant thereof or a fragment thereof ~~and/or one of its variants and/or fragments dissolved or suspended in aqueous medium~~ by means of a precipitation reagent,

wherein said anti-EGFR antibody is a chimeric monoclonal antibody c225 or a humanized monoclonal antibody h425.

Claim 2. (Currently Amended) ~~Solid form~~ The crystal according to Claim 1, ~~characterised in that use is made of salts, polymers and/or organic solvents as~~ wherein the precipitation reagent comprises a salt, a polymer, an organic solvent, or a combination thereof.

Claim 3. (Currently Amended) ~~Solid form~~ The crystal according to Claim 2, ~~characterised in that use is made of~~ wherein the precipitation reagent comprises ammonium sulfate, sodium acetate, sodium citrate, potassium phosphate, PEG and/or ethanol ~~as precipitation reagent~~.

Claim 4. (Canceled)

Claim 5. (Canceled)

Claim 6. (Canceled)

Claim 7. (Canceled)

Claim 8. (Currently Amended) ~~Solid form~~ The crystal according to Claim 1 [[~~7~~]], ~~characterised in that~~ wherein the anti-EGFR antibody is Mab C225 (cetuximab) or Mab h425 (EMD 72000).

Claim 9. (Currently Amended) ~~Process~~ A process for the preparation of a ~~solid form~~ crystal of an anti-EGFR antibody or a variant thereof or a fragment thereof ~~and/or one of its variants and/or~~

~~fragments~~ which ~~results in~~ forms a biologically active antibody protein when dissolved or suspended ~~through dissolution or suspension~~ in an aqueous medium, comprising

precipitating an aqueous solution or suspension of said anti-EGFR antibody or a variant thereof or a fragment thereof by means of a precipitation reagent, and

separating the precipitation product

~~characterised in that the antibody and/or one of its variants and/or fragments dissolved or suspended in aqueous solution is precipitated by means of a precipitation reagent, and the precipitation product is separated off~~.

Claim 10. (Currently Amended) ~~Process~~ A process according to Claim 9, ~~characterised in that use is made of~~ wherein the precipitation reagent comprises ammonium sulfate, PEG and/or ethanol ~~as precipitation reagent~~.

Claim 11. (Currently Amended) ~~Process~~ A process according to Claim 9, ~~characterised in that the process~~ which is carried out in batch format.

Claim 12. (Currently Amended) ~~Solid form according to Claim 1 as~~ A storage-stable medicament which comprises a crystal of claim 1 together with a stabilizing agent .

Claim 13. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical preparation ~~comprising at least one solid form~~ which comprises the crystal according to Claim 1, wherein said crystal is in crystalline, soluble, or suspended form, and a pharmaceutically acceptable carrier ~~in precipitated non-crystalline, precipitated crystalline or in soluble or suspended form, and optionally excipients and/or adjuvants and/or further pharmaceutical active ingredients~~.

Claim 14. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical preparation according to Claim 13, wherein said crystal is in soluble or suspended form, ~~characterised in that~~ wherein the anti-EGFR antibody concentration is 10 – 200 mg/ml.

Claim 15. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical preparation according to Claim 14, ~~characterised in that~~ wherein the anti-EGFR antibody concentration is 50 – 150 mg/ml.

Claim 16. (Cancelled)

Claim 17. (Withdrawn, Currently Amended) ~~Use according to Claim 16 for the preparation of a medicine~~ A method for the treatment and/or prophylaxis of ~~tumours and/or tumour metastases~~ a tumor or a tumor metastasis in a subject in need thereof, comprising administering to said subject a crystal of claim 1.

Claim 18. (Withdrawn, Currently Amended) ~~Use~~ A method according to Claim 17, ~~where the tumour is selected from the group consisting of~~ wherein the tumor is brain ~~tumour, tumour~~ tumor, tumor of the urogenital tract, ~~tumour~~ tumor of the lymphatic system, stomach ~~tumour~~ tumor, laryngeal ~~tumour~~ tumor, monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinoma, pancreatic cancer, glioblastoma ~~and~~ or breast carcinoma.

Claim 19. (New) The crystal according to Claim 1, wherein the anti-EGFR antibody fragment comprises a bivalent $F(ab')_2$ fragment, a monovalent Fab fragment or an Fc fragment of said anti-EGFR antibody.

Claim 20. (New) The crystal according to Claim 1, wherein the anti-EGFR antibody fragment comprises an EGFR-binding portion of said anti-EGFR antibody.

Claim 21. (New) The crystal according to Claim 1, wherein the anti-EGFR antibody variant comprises a PEGylated anti-EGFR antibody.

Claim 22. (New) The crystal according to Claim 1, which has a size of 50–200 μm.